A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
The worldwide use of constant intrapartum ZDV infusions to prevent transmission is not practical or feasible. Approximately 18% of the women in the ACTG 076 trial missed their IV ZDV infusions, even at experienced ACTG sites. There is an urgent need to establish a more practical method of delivering ZDV during labor and delivery that, at minimum, will approximate the rate of ZDV administration utilized in ACTG 082. In the future, this would enable women to start an intensive ZDV regimen during early labor, even prior to reaching the hospital.
Cohort 1: Women in active labor receive 3 doses...
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria
- A woman may be eligible for this study if:
- • She is HIV-positive.
- • She is at least 34 weeks pregnant.
- • She has a history of at least 4 weeks of continuous oral ZDV during her current pregnancy and tolerated it well.
- • She has given consent for her newborn to participate in this study. (The father must also give consent if he is available after reasonable attempts to contact him. A woman under 18 needs the consent of a parent or legal guardian for her and her infant to participate.)
- • Exclusion Criteria
- A woman will not be eligible for this study if:
- • She is taking part in another study of HIV treatment during pregnancy.
- • Her infant has a life-threatening illness indicated in an ultrasound.
- • Her infant does not appear to be growing normally in the womb.
- • She has a cesarean section.
- • She has abnormal blood test results.
- • She has severe nausea, vomiting, or other problems of the stomach and intestines at the time of study entry.
- • She has an active opportunistic (AIDS-related) infection or other serious infection at the time of study entry.
- • The study staff cannot find a usable vein.
- • The study doctor feels that she cannot take drugs by mouth.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Jolla, California, United States
Los Angeles, California, United States
San Francisco, California, United States
Miami, Florida, United States
Memphis, Tennessee, United States
San Juan, , Puerto Rico
Newark, New Jersey, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Norfolk, Virginia, United States
San Francisco, California, United States
Patients applied
Trial Officials
Mark Mirochnick
Study Chair
Pamela Boyer
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials